One prominent PPARβ/δ-selective agonist is seladelpar (MBX-8025), which is currently in clinical phase 2/3 for primary biliary cirrhosis, and has previously been shown to improve the insulin sensitivity and dyslipidemia in overweight subjects [130]. Here, PPARD is linked to metabolic syndrome.